Atlas Trials

T-DM1 and Non-pegylated Liposomal Doxorubicin in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer

Clinical trial NCT02562378 · COMPLETED

Trial details

NCT number
NCT02562378
Sponsor
MedSIR
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Breast Cancer
Start date
2015-10-01
Primary completion
2018-12-01
Enrollment
15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.